Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Pain relief without side effects ‘breakthrough’

Pain relief without side effects ‘breakthrough’

Scientists claim to have developed super-strength ibuprofen that can be taken every day without damaging the stomach, a breakthrough that could give pain relief to 30million people worldwide.

People suffering from conditions such as rheumatoid arthritis and osteoarthritis need to take a large number of tablets to numb the pain they suffer every day.

However, excessive use of the drug can cause gastrointestinal problems, and can even lead to death.

Last night, Oxford Pharmascience revealed that it had developed a 400mg ibuprofen pill that dramatically reduces the risk of any side effects.

The company, which specialises in taking medicines and making them better, safer and easier to take, announced details of the “gastric-safe” tablets to the stock market yesterday.

One of the UK’s leading arthritis charities, Arthritis Care UK, has given a cautious welcome to the development.

Chief executive Judi Rhys said: “Coping with the pain of arthritis is a massive challenge for the estimated 10million people in the UK with arthritis. Taking medication is clearly a route that many take and any news of safer ways to do this are of course welcome.

“But this reformulation of ibuprofen is still to be tested at a clinical level, so there are presumably still some years before it becomes available.”

Ibuprofen belongs to a medicine group called non-steroidal anti-inflammatory drugs (NSAIDs), which are one of the most widely used classes of drugs, with more than 30million users worldwide consuming NSAIDs each day and annual sales of £7.4billion.

Despite this commercial success, long-term use of NSAIDs causes well-documented gastrointestinal side effects.

These include ulcers and bleeding and lead to significant morbidity and mortality in many patients.

Marcelo Bravo, chief technology officer of Oxford Pharmascience, said: “We are on track to take 400mg ibuprofen tablets into clinical pilot testing in early 2014.”